Outcomes After Aspirin Discontinuation Among Baseline Users in Contemporary Primary Prevention Aspirin Trials: A Meta-Analysis

Circulation. 2024 Feb 27;149(9):722-724. doi: 10.1161/CIRCULATIONAHA.123.065420. Epub 2024 Feb 26.

Authors

Ruth Campbell¹, Mark R Nelson^{2

3}, John J McNeill³, John W McEvoy¹

Affiliations

¹ National Institute for Prevention and Cardiovascular Health and School of Medicine, University of Galway, Ireland (R.C., J.W.M.E.).
² Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia (M.R.N.).
³ Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (M.R.N., J.J.M.N.).

PMID: 38408145
PMCID: PMC10901451 (available on 2025-02-27)
DOI: 10.1161/CIRCULATIONAHA.123.065420

No abstract available

Keywords: aspirin; cardiovascular diseases; primary prevention.

Publication types

Meta-Analysis
Research Support, Non-U.S. Gov't

MeSH terms

Aspirin* / adverse effects
Cardiovascular Diseases* / prevention & control
Humans
Platelet Aggregation Inhibitors / adverse effects
Primary Prevention
Research Design
Risk Factors

Substances

Aspirin
Platelet Aggregation Inhibitors

Grants and funding